journal
https://read.qxmd.com/read/38520796/eltrombopag-treatment-in-thrombocytopenia-following-hematopoietic-stem-cell-transplantation-a-multicenter-real-world-experience
#1
JOURNAL ARTICLE
Ebru Kilic Gunes, Sureyya Yigit Kaya, Fatih Yaman, Mustafa Kemal Yeniay, Kurtulus Vural, Melda Comert, Omur Gokmen Sevindik, Neslihan Andic, Simten Dagdas, Ilknur Nizam Ozen, Leylagul Kaynar, Filiz Yavasoglu, Gulsum Ozet, Volkan Karakus, Meltem Ayli
INTRODUCTION: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT. MATERIAL-METHOD: A total of 73 patients from 5 centers who underwent autologous or allogeneic stem cell transplantation, had no primary disease relapse, all of whom had neutrophil engraftment, complete chimerism, and who were diagnosed with Prolonged Isolated Thrombocytopenia (PIT) or Secondary Failure Of Platelet Recovery (SFPR) were included in the study...
March 15, 2024: Leukemia Research
https://read.qxmd.com/read/38499457/pracinostat-combined-with-azacitidine-in-newly-diagnosed-adult-acute-myeloid-leukemia-aml-patients-unfit-for-standard-induction-chemotherapy-primula-phase-iii-study
#2
JOURNAL ARTICLE
Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced age, comorbidities, and/or risk factors. However, response rates and survival remain dismal. Pre-clinical studies indicate the epigenetic combination of HMAs and HDAC inhibitors induce re-expression of silenced genes synergistically. The activity of pracinostat, an oral pan-HDAC inhibitor, has been shown in xenograft tumor models of AML and promising efficacy was seen in a Phase 2 study...
March 12, 2024: Leukemia Research
https://read.qxmd.com/read/38493755/investigations-of-the-prognostic-value-of-runx1-mutation-in-acute-myeloid-leukemia-patients-data-from-a-real-world-study
#3
JOURNAL ARTICLE
Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Yan-Li Xu, Kai-Wen Tan, Yan-Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Song-Bai Liu, Jia-Jun Qi, Hai-Ping Dai, Sheng-Li Xue
RUNX1 is one of the recurrent mutated genes in newly diagnosed acute myeloid leukemia (AML). Although historically recognized as a provisional distinct entity, the AML subtype with RUNX1 mutations (AML-RUNX1mut ) was eliminated from the 2022 WHO classification system. To gain more insight into the characteristics of AML-RUNX1mut , we retrospectively analyzed 1065 newly diagnosed adult AML patients from the First Affiliated Hospital of Soochow University between January 2017 and December 2021. RUNX1 mutations were identified in 112 patients (10...
March 12, 2024: Leukemia Research
https://read.qxmd.com/read/38492495/cd38-and-bcl2-expression-guides-treatment-with-daratumumab-and-venetoclax-in-tagraxofusp-refractory-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-featuring-dynamic-loss-of-cd123
#4
LETTER
Xiaoyi Hu, Asiri Ediriwickrema, Atif Saleem, Brent Tan, Naveen Pemmaraju, Gabriel N Mannis
No abstract text is available yet for this article.
March 11, 2024: Leukemia Research
https://read.qxmd.com/read/38484432/efficacy-and-safety-of-bosutinib-in-patients-treated-with-prior-imatinib-and-or-dasatinib-and-or-nilotinib-subgroup-analyses-from-the-phase-4-byond-study
#5
JOURNAL ARTICLE
B Douglas Smith, Tim H Brümmendorf, Gail J Roboz, Carlo Gambacorti-Passerini, Aude Charbonnier, Andrea Viqueira, Eric Leip, Simon Purcell, Erinn Hoag Goldman, Francis Giles, Thomas Ernst, Andreas Hochhaus, Gianantonio Rosti
The BYOND study evaluated the efficacy and safety of bosutinib 500 mg once daily in patients with chronic myeloid leukemia (CML) resistant/intolerant to prior tyrosine kinase inhibitors (TKIs). These post-hoc analyses assessed the efficacy and safety of bosutinib by resistance or intolerance to prior TKIs (imatinib-resistant vs dasatinib/nilotinib-resistant vs TKI-intolerant), and cross-intolerance between bosutinib and prior TKIs (imatinib, dasatinib, nilotinib), in patients with Philadelphia chromosome-positive chronic phase CML...
March 11, 2024: Leukemia Research
https://read.qxmd.com/read/38479337/expression-of-the-chemokine-receptor-ccr1-decreases-sensitivity-to-bortezomib-in-multiple-myeloma-cell-lines
#6
JOURNAL ARTICLE
Mara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, Vasilios Panagopoulos, Craig T Wallington-Gates, Andrew Spencer, Sandra M Dold, Monika Engelhardt, Kate Vandyke, Andrew C W Zannettino
BACKGROUND: The proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a barrier to successful treatment in many patients. Our previous studies have shown that elevated expression of the chemokine receptor CCR1 in MM plasma cells in newly diagnosed MM patients is associated with poor prognosis. Here, we hypothesised that the poor prognosis conferred by CCR1 expression is, in part, due to a CCR1-mediated decrease in MM plasma cell sensitivity to bortezomib...
March 7, 2024: Leukemia Research
https://read.qxmd.com/read/38460432/addition-of-single-dose-gemtuzumab-ozogamicin-to-intensive-induction-chemotherapy-in-core-binding-factor-acute-myeloid-leukemia
#7
JOURNAL ARTICLE
Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy
In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center retrospective analysis to compare outcomes of patients with CBF-AML treated with intensive induction chemotherapy, with or without a single dose of GO 3 mg/m2 , during induction only...
February 28, 2024: Leukemia Research
https://read.qxmd.com/read/38422882/phytostilbenes-in-lymphoma-focuses-on-the-mechanistic-and-clinical-prospects-of-resveratrol-pterostilbene-piceatannol-and-pinosylvin
#8
REVIEW
Pouya Goleij, Pantea Majma Sanaye, Mehregan Babamohamadi, Mohammad Amin Khazeei Tabari, Roshanak Amirian, Aryan Rezaee, Hamed Mirzaei, Alan Prem Kumar, Gautam Sethi, Sarvin Sadreddini, Philippe Jeandet, Haroon Khan
Lymphoma is a cancer affecting the lymphatic system that fights infections and diseases. In addition to surgery, radiotherapy, and chemotherapy, novel approaches have recently been investigated, such as phytostilbenes in treating lymphoma. Phytostilbenes are natural compounds present in various plants and have been shown to have different therapeutic effects, including anticancer properties. Resveratrol is a main phytostilbene with various derivates followed by pterostilbene and piceatannol. Studies have revealed that phytostilbenes can suppress the growth and proliferation of lymphoma cells by inducing apoptosis and inhibiting specific enzyme activity in cancer cell survival...
February 24, 2024: Leukemia Research
https://read.qxmd.com/read/38422881/a-critical-evaluation-of-the-efs-endpoint-in-aml-does-induction-treatment-failure-timing-have-a-profound-impact-on-study-design-and-results
#9
JOURNAL ARTICLE
Yulia Sidi, Cassie Dong, Yujun Wu, Douglas V Faller
Despite emerging novel therapies, treating acute myeloid leukemia (AML) remains challenging. Complexities persist in designing pivotal clinical trials and establishing acceptable endpoints for AML. Recent FDA guidance for drug and biological products development for AML outlines considerations for trial design. The guidance defines overall survival (OS) and event-free survival (EFS) as endpoints representing clinical benefit for AML therapies without curative intent. We highlight the EFS definition, particularly the assignment of day 1 as the event date for patients with induction treatment failures (ITFs), as recommended in the guidance...
February 23, 2024: Leukemia Research
https://read.qxmd.com/read/38430640/kras-mutations-autoimmunity-and-female-sex-in-chronic-myelomonocytic-leukemia
#10
LETTER
Afaf E G Osman, Anton Rets, Ami B Patel
No abstract text is available yet for this article.
February 22, 2024: Leukemia Research
https://read.qxmd.com/read/38442593/clinical-outcomes-of-patients-with-acute-myeloid-leukemia-and-cardiovascular-disease
#11
JOURNAL ARTICLE
Gabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, James Childress, Tahreem Iqbal, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Jennie Y Law, Seung Tae Lee, Vu H Duong, Maria R Baer, Sandrine Niyongere
Incidence of both acute myeloid leukemia (AML) and cardiovascular disease (CVD) increases with age. We evaluated whether pre-existing CVD impacts clinical outcomes in AML. We retrospectively evaluated 291 consecutive adult AML patients treated at our institution, 2014-2020. Pretreatment comorbidities were identified by chart review. Outcomes included complete remission (CR) and CR with incomplete count recovery (CRi) rates, disease-free survival (DFS), overall survival (OS) and incidence of cardiovascular adverse events...
February 20, 2024: Leukemia Research
https://read.qxmd.com/read/38382169/adipose-tissue-indices-predict-prognosis-in-hodgkin-lymphoma
#12
JOURNAL ARTICLE
Demircan Özbalcı, Mehmet Erdoğan, Emine Güçhan Alanoğlu, Sevim Süreyya Şengül, Kamuran Yüceer, Hande Nur Eroğlu, Samet Yağcı
INTRODUCTION BACKGROUND: This study evaluated the impact of adipose tissue indices on prognosis of HL. METHODS: Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression free and overall survival...
February 15, 2024: Leukemia Research
https://read.qxmd.com/read/38452534/proteomic-analysis-of-adult-t-cell-leukemia-lymphoma-a-biomarker-identification-strategy-based-on-preparation-and-in-solution-digestion-methods-of-total-proteins
#13
JOURNAL ARTICLE
Haruka Sudo, Yasuhiro Tonoyama, Emi Ikebe, Hiroo Hasegawa, Hidekatsu Iha, Yo-Ichi Ishida
Adult T-cell leukemia/lymphoma (ATL), caused by human T-cell leukemia virus type-1 (HTLV-1) infection, is a malignant hematologic cancer that remains difficult to cure. We herein established a biomarker identification strategy based on the total cell proteomics of cultured ATL cells to search for novel ATL biomarkers. Four protocols with a combination of selected conditions based on lysis buffers and addition agents for total cell proteomics were used for a differential analysis between the ATL cell group (consisting of 11 cell lines), HTLV-1-infected cell group (consisting of 6 cell lines), and HTLV-1-negative cell group (consisting of 6 cell lines)...
February 12, 2024: Leukemia Research
https://read.qxmd.com/read/38368721/bortezomib-modulated-the-autophagy-lysosomal-pathway-in-a-tfeb-dependent-manner-in-multiple-myeloma
#14
JOURNAL ARTICLE
Rongjuan Zhang, Xinhong Yang, Xiaomin Shi, Enhong Xing, Lihong Wang, Changlai Hao, Zhihua Zhang
OBJECTIVE: To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment. METHODS: MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome sequencing was carried out. Additionally, TFEB target genes were predicted using the GTRD(https://gtrd...
February 12, 2024: Leukemia Research
https://read.qxmd.com/read/38442594/clinical-features-and-management-of-germline-cebpa-mutated-carriers
#15
JOURNAL ARTICLE
Lili Pan, Yining Li, Huiying Gao, Xiaolin Lai, Yuanhua Cai, Zhixiang Chen, Xiaofan Li, Shao-Yuan Wang
Familial acute myeloid leukemia (AML) pedigrees with germline CCAAT/enhancer-binding protein-α (CEBPA) mutation have been rarely reported due to insufficient knowledge of their clinical features. Here, we report two Chinese families with multiple AML cases carrying germline CEBPA mutations, one of which had 11 cases spanning four consecutive generations. Additionally, we collected clinical data of 57 AML patients from 22 families with germline CEBPA mutations, with 58.3% of them harboring double CEBPA mutations...
February 3, 2024: Leukemia Research
https://read.qxmd.com/read/38281466/emergence-of-secondary-fusions-in-chronic-myeloid-leukemia-as-a-driver-of-tyrosine-kinase-inhibitor-resistance-and-blast-crisis-transformation
#16
LETTER
Lara Boucher, Laura Rozalska, Nathalie Sorel, Gaëlle Olivier, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault, Jean-Claude Chomel
No abstract text is available yet for this article.
January 23, 2024: Leukemia Research
https://read.qxmd.com/read/38244295/when-the-devil-is-in-the-details-similarities-and-differences-between-who-and-icc-classifications-of-aml
#17
LETTER
Sergio Ramos-Cillan, Daniel Láinez-González, Laura Solan, Carlos Blas, Rocío Salgado, Tamara Castaño, Javier Cornago, Pilar Llamas, Juan Manuel Alonso-Dominguez
No abstract text is available yet for this article.
January 17, 2024: Leukemia Research
https://read.qxmd.com/read/38232613/identification-of-unique-molecular-heterogeneity-of-human-cd79-the-signaling-component-of-the-human-b-cell-antigen-receptor-bcr-and-synergistic-potentiation-of-the-cd79-targeted-therapy-of-b-cell-tumors-by-co-targeting-of-cd79a-and-cd79b
#18
JOURNAL ARTICLE
Ben K Seon, Morihiro Okazaki, Jill Duzen, Fumihiko Matsuno, Andrew K L Goey, Orla Maguire
We identified unique molecular heterogeneity of CD79 of human B cell antigen receptor (BCR) that may open a new approach to the ongoing CD79b-targeted therapy of B cell tumors. The primary purpose of the present study is to gain new information valuable for the enhanced CD79-targeted therapy. The molecular heterogeneity of CD79 was identified by sequential immunoprecipitation of BCR by use of anti-CD79b monoclonal antibody (mAb) SN8 and anti-CD79a mAb SN8b. SN8 is the antibody component of polatuzumab vedotin, an anti-CD79b antibody drug conjugate, that has been widely used for therapy of diffuse large B-cell lymphoma (DLBCL)...
January 9, 2024: Leukemia Research
https://read.qxmd.com/read/38215555/artificial-intelligence-based-prediction-models-for-acute-myeloid-leukemia-using-real-life-data-a-dataml-registry-study
#19
JOURNAL ARTICLE
Ibrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, François Vergez, Suzanne Tavitian, Laëtitia Largeaud, Audrey Bidet, Jean-Baptiste Rieu, Isabelle Luquet, Nicolas Lechevalier, Eric Delabesse, Audrey Sarry, Anne-Charlotte De Grande, Emilie Bérard, Arnaud Pigneux, Christian Récher, David Simoncini, Sarah Bertoli
We designed artificial intelligence-based prediction models (AIPM) using 52 diagnostic variables from 3687 patients included in the DATAML registry treated with intensive chemotherapy (IC, N = 3030) or azacitidine (AZA, N = 657) for an acute myeloid leukemia (AML). A neural network called multilayer perceptron (MLP) achieved a prediction accuracy for overall survival (OS) of 68.5% and 62.1% in the IC and AZA cohorts, respectively. The Boruta algorithm could select the most important variables for prediction without decreasing accuracy...
January 9, 2024: Leukemia Research
https://read.qxmd.com/read/38199929/corrigendum-to-real-world-clinical-outcomes-with-enasidenib-in-relapsed-or-refractory-acute-myeloid-leukemia-leuk-res-2022-106946
#20
Andrew J Klink, Ajeet Gajra, Russell L Knoth, Landon Marshall, Ying Hou, Ali McBride, Ronda Copher
No abstract text is available yet for this article.
January 9, 2024: Leukemia Research
journal
journal
27133
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.